Groundbreaking Study Reveals $167 Trillion in Societal Value Generated by American Medical Innovation

WASHINGTON, D.C. - A pioneering new study by University of Chicago economist Dr. Tomas Philipson, commissioned by the U.S. Chamber of Commerce, finds that American medical innovation has delivered $167.5 trillion in societal value based on a 30-year horizon across four major medical diseases. The analysis creates a comprehensive new framework and quantifies societal value, based on the extraordinary gains generated through advancements in treatments for HIV, heart disease, breast cancer, and obesity-including longer lives, improved quality of life, productivity growth, and strengthened federal tax revenues.

"This study illuminates the profound human impact of medical innovation-transforming once-fatal diagnoses into manageable conditions and giving patients decades of life they wouldn't have had otherwise," said Neil Bradley, executive vice president and chief policy officer at the U.S. Chamber of Commerce. "These breakthroughs represent hope for millions of families and have fueled economic growth by keeping Americans healthier."

Dr. Tomas J. Philipson, Professor at the University of Chicago Harris School of Public Policy, emphasized the unparalleled value created by the innovation ecosystem. "For most people, health is their most valuable asset; material well-being means little when faced with a serious disease or a shortened life. The industries driving medical innovation create value few others can match. This study is the first to quantify the immense societal benefits of key medical advancements over recent decades and demonstrates the need for governments to work collaboratively with the industries advancing medical progress."

Key Findings

• Medical innovations in four disease areas: HIV, heart disease, breast cancer, and obesity generated $167.5 trillion in societal value over a 30-year horizon across all four disease areas-equal to $5.6 trillion annually or $16,447 per person per year. These figures are calculated using a Value of a Statistical Year of Life, a common tool used by government agencies when doing cost benefit analysis to quantify the monetary value of each year of life gained or extended because of policy changes.
• HIV patients now live an additional 40 years on average; heart disease treatments have added critical working years; breast cancer survival has improved by seven years on average.
• These innovations drove $10.75 trillion in productivity gains over the 30-year horizon, supporting a stronger workforce and long-term economic growth.
• Breakthroughs in the four disease areas generated $2.01 trillion in federal tax revenue over the 30-year horizon.
• Every dollar invested in medical R&D has returned 27 dollars in societal value-demonstrating that innovation is an investment, not a cost.

Innovation at Risk from Harmful MFN-Style Price Controls

Despite these gains, ongoing progress could be jeopardized by policies like Most-Favored Nation (MFN) pricing, which would import foreign price controls on medicines into the U.S. healthcare system, ultimately undermining this innovative ecosystem. Such measures would reduce incentives for research and development, cut clinical trial activity by up to 75%, delay or restrict patient access to future treatments, and threaten high-quality jobs and America's global leadership in life sciences.

"MFN price controls would undermine the very innovation that has delivered life-saving breakthroughs for millions of Americans," Bradley added. "Policymakers should reject MFN and instead pursue market-based solutions that preserve medical innovation, support patient access, and ensure the next generation of treatments is developed here in the United States."

To download the full report, click here.